Fred Saad, MD, FRCS

Efficacy and safety results from the phase 1 PAnTHA study presented at 2026 ASCO GU.

Seven-year follow-up data on over 1400 patients show radium-223's long-term safety, with a low 2% secondary malignancy rate, reflecting real-world use.

Fred Saad, MD, FRSC, discusses the findings of a biomarker analysis of the PROpel trial in patients with metastatic castration-resistant prostate cancer.

Fred Saad, MD, FRSC, discusses the key biomarkers looked at in an analysis of the phase 3 PROpel trial analyzing olaparib plus abiraterone to treat patients with metastatic castration resistant prostate cancer.

Fred Saad, MD, FRCS, University of Montreal, discusses the benefit of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).